Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX – Get Free Report) shares shot up 4.3% during mid-day trading on Monday . The company traded as high as $0.72 and last traded at $0.72. 794 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 8,179 shares. The stock had previously closed at $0.69.
Eloxx Pharmaceuticals Stock Performance
The business has a fifty day simple moving average of $0.79 and a 200-day simple moving average of $0.89. The firm has a market cap of $2.26 million, a price-to-earnings ratio of -0.08 and a beta of 2.66.
Eloxx Pharmaceuticals Company Profile
Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations.
Read More
- Five stocks we like better than Eloxx Pharmaceuticals
- Using the MarketBeat Dividend Tax Calculator
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- ETF Screener: Uses and Step-by-Step Guide
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
